Director and Affiliates Invest $1M in Highly Dilutive Private Placement
INAB has more than doubled off its 52-week low of $1.17.
Summary
A director and related entities invested $1 million in IN8BIO's recent private placement, acquiring a significant stake as the company raised substantial capital.
Key Events · Ownership and Investor Activity · INAB
-
Director and Affiliates Invest
Emily Fairbairn, a director, along with Malcom Fairbairn and their charitable trust, invested $1 million in IN8BIO's private placement.
-
Significant Capital Raise
The investment was part of a larger private placement that raised approximately $20.1 million for the company.
-
Substantial Beneficial Ownership
The reporting persons now beneficially own approximately 7.5% of the company's common stock.
-
Dilutive Financing
The private placement, priced at $1.38 per share, is highly dilutive but provides critical funding for the company's operations.
Analysis · INAB · Life Sciences
Emily Fairbairn, a director of IN8BIO, along with Malcom Fairbairn and their charitable trust, collectively invested $1 million in the company's private placement. This investment, made at $1.38 per share, is part of a larger financing round that raised approximately $20.1 million. While the private placement is highly dilutive for existing shareholders, the successful capital raise provides crucial funding for IN8BIO's operations. The participation of a director and significant investors in this round signals confidence in the company's future despite the dilutive nature of the offering.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INAB was trading at $2.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $1.17 to $12.53. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.